4//SEC Filing
Heft Robert 4
Accession 0001104659-20-042763
CIK 0001481512other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 9:00 AM ET
Size
12.4 KB
Accession
0001104659-20-042763
Insider Transaction Report
Form 4
Heft Robert
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−22,857→ 0 totalExercise: $2.87Exp: 2026-03-10→ Common Stock (22,857 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $9.90Exp: 2028-06-28→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $22.37Exp: 2027-06-20→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $19.88Exp: 2029-06-11→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
- [F2]Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Documents
Issuer
Ra Pharmaceuticals, Inc.
CIK 0001481512
Entity typeother
Related Parties
1- filerCIK 0001688203
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 9:00 AM ET
- Size
- 12.4 KB